Identification of a locus on distal mouse chromosome 12 that controls resistance to tumor necrosis factor-induced lethal shock

Genomics

Volumn 55, Issue 3, 1999, Pages 284-289

  Libert, Qaude ^a   Wielockx, Ben ^a   Hammond, Geoffrey L ^b   Brouckaert, Peter ^a,b   Rers, Walter ^c   Bliott, Rosemary W ^c  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Fbswell Park Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR; TRANSCORTIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CHROMOSOME 12; FEMALE; GENE LOCUS; GENE MAPPING; HYPOTHERMIA; IMMUNOGENETICS; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT; SHOCK;

ANIMALIA; MURINAE; RODENTIA;

EID: 0033082277     PISSN: 08887543     EISSN: None     Source Type: Journal    
DOI: 10.1006/geno.1998.5677     Document Type: Article

References (25)

1. 1-protease inhibitor is not an acute phase reactant. Arch. Biochem. Biophys. 246: 488-493.
2. Beutler, B., Milsark, I. W., and Cerami, A. C. (1985). Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871.
3. Brouckaert, P. G. G., Leroux-Roels, G. G., Guisez, Y., Tavernier, J., and Fiers, W. (1986). In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int. J. Cancer 38: 763-769.
4. Brouckaert, P. G., Libert, C., Everaerdt, B., Takahashi, N., and Fiers, W. (1989). A role for interleukin 1 in the in vivo actions of tumor necrosis factor. Lymphokine Res. 8: 269-274.
5. Brouckaert, P., Everaerdt, B., and Fiers, W. (1992). The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor. Ear. J. Immunol. 22: 981-986.
6. Brouckaert, P., Libert, C., Cauwels, A., Everaerdt, B., Van Molle, W., Ameloot, P., Gansemans, Y., Grijalba, B., Takahashi, N., Truong, M.-J., Van Leuven, P., and Fiers, W. (1996). Inhibition of and sensitization to the lethal effects of tumor necrosis factor. J. Inflam. 47: 18-26.
7. Creaven, P. J., Brenner, D. E., Cowens, J. W., Hüben, R. P., Wolf, R. M., Takita, H., Arbuck, S. G., Razak, M. S., and Proefrock, A. D. (1989). A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother. Pharmacol. 23: 186-191.
8. Fiers, W. (1995). Biologic therapy with TNF: Preclinical studies. In "Biologic Therapy of Cancer" (V. T. DeVita Jr., S. Hellman, and
9. S. A. Rosenberg, Eds.), 2nd ed., pp. 295-327, Lippincott, Philadelphia.
10. Fransen, L., Van der Heyden, J., Ruysschaert, R., and Fiers, W. (1986). Recombinant tumor necrosis factor: Its effect and its synergism with Interferon-γ on a variety of normal and transformed human cell lines. Eur. J. Cancer Clin. Oncol. 22: 419-426.
11. Hammond, G. L. (1995). Potential functions of plasma steroid-binding proteins. Trends Endocrlnol. Metab. 6: 298-304.
12. Hammond, G. L., Smith, C. L., Paterson, N. A. M., and Sibbald, W. J. (1990). A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J. Clin. Endocrinol. Metab. 71: 34-39.
13. Hill, R. E., Shaw, P. H., Earth, R. K, and Hastie, N. D. (1985). A genetic locus closely linked to a protease inhibitor gene complex controls the level of multiple RNA transcripts. Mol. Cell. Biol. 5: 2114-2122.
14. Landegren, U. (1984). Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J. Immunol. Methods 67: 379-388.
15. Lander, E., and Kruglyak, L. (1995). Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. Nat. Genet. 11: 241-247.
16. Leist, M., Gantner, F., Jilg, S., and Wendel, A. (1995). Activation of the 55 kDa TNF receptor is necessary and sufficient for TNFinduced liver failure, hepatocyte apoptosis, and nitrite release. J. Immunol. 154: 1307-1316.
17. Lejeune, F., Liénard, D., Eggermont, A., Schraffordt Koops, H., Kroon, B., Gérain, J., Rosenkaimer, F., and Schmilz, P. (1994). Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ. Shock 43: 191-197.
18. Libert, C., Van Bladel, S., Brouckaert, P., Shaw, A., and Fiers, W. (1991). Involvement of the liver, but not of IL-6, in IL-1-induced desensitization to the lethal effects of tumor necrosis factor. J. Immunol. 146: 2625-2632.
19. Libert, C., Takahashi, N., Cauwels, A., Brouckaert, P., Bluethmann, H., and Fiers, W. (1994). Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur. J. Immunol. 24: 2237-2242.
20. 1-Antitrypsin inhibits the lethal response to TNF in mice. J. Immunol. 157: 5126-5129.
21. Manly, K. F., and Elliott, R. W. (1991). RI manager, a microcomputer program for analysis of data from recombinant inbred strains. Mamm. Genome 1: 123-126.
22. Takahashi, N., Brouckaert, P., and Fiers, W. (1991). Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice. Cancer Res. 51: 2366-2372.
23. Van Snick, J., Cayphas, S., Vink, A., Uyttenhove, C., Coulie, P. G., Rubira, M. R., and Simpson, R. J. (1986). Purification and NH2terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. USA 83: 9679-9683.
24. Vassalli, P. (1992). The pathophysiology of tumor necrosis factors. Anna. Rev. Immunol. 10: 411-452.
25. Yamamoto, K., Suzuki, Y., and Sinohara, H. (1988). Synthesis of contrapsin and α-1-antiproteinase in inflamed and tumor-bearing mice. Biochem. Int. 16: 921-928.